ID   MG87/CD20
AC   CVCL_C6XH
DR   Wikidata; Q117704703
RX   Patent=US8329181;
RX   PubMed=26659273;
CC   Transfected with: HGNC; 7315; MS4A1.
CC   Derived from site: In situ; Whole embryo; UBERON=UBERON_0000922.
CC   Cell type: Fibroblast; CL=CL_0000057.
CC   Breed/subspecies: NIH Swiss.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_U510 ! MG87
SX   Male
AG   Embryo
CA   Spontaneously immortalized cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   Patent=US8329181;
RA   Martin J.H., Wang L.-H., Stevens S., Allison E.M.;
RT   "Methods for treating B-cell lymphoma by administering an anti-CD20
RT   antibody.";
RL   Patent number US8329181, 11-Dec-2012.
//
RX   PubMed=26659273; DOI=10.1038/srep17943;
RA   Smith E.J., Olson K., Haber L.J., Varghese B., Duramad P.,
RA   Tustian A.D., Oyejide A., Kirshner J.R., Canova L., Menon J.,
RA   Principio J., MacDonald D., Kantrowitz J., Papadopoulos N.J., Stahl N.,
RA   Yancopoulos G.D., Thurston G., Davis S.;
RT   "A novel, native-format bispecific antibody triggering T-cell killing
RT   of B-cells is robustly active in mouse tumor models and cynomolgus
RT   monkeys.";
RL   Sci. Rep. 5:17943-17943(2015).
//